Eli Lilly and Company $LLY Shares Sold by MinichMacGregor Wealth Management LLC

Key Points

• MinichMacGregor Wealth Management LLC reduced its holdings in Eli Lilly by 9.6%, selling 1,110 shares during the 2nd quarter, bringing its total ownership to 10,464 shares valued at $8,157,000.
• Eli Lilly reported a 12-month revenue increase of 37.6% year-over-year, with earnings per share surpassing estimates in its last quarterly report, announcing $6.31 against an expected $5.59.
• Insiders at Eli Lilly have made significant purchases, with Director Gabrielle Sulzberger acquiring 117 shares at $641.18 each, and EVP Daniel Skovronsky buying 1,000 shares at $634.40 each, indicating confidence in the company's future performance.

MinichMacGregor Wealth Management LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,464 shares of the company's stock after selling 1,110 shares during the quarter. Eli Lilly and Company makes up about 1.7% of MinichMacGregor Wealth Management LLC's holdings, making the stock its 29th largest position. MinichMacGregor Wealth Management LLC's holdings in Eli Lilly and Company were worth $8,157,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hobbs Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC raised its stake in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC grew its holdings in Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the period. Finally, Tennessee Valley Asset Management Partners raised its position in shares of Eli Lilly and Company by 2.7% in the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock worth $407,000 after buying an additional 13 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last ninety days. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

LLY opened at $724.73 on Friday. The firm has a market capitalization of $685.93 billion, a P/E ratio of 47.37, a PEG ratio of 0.99 and a beta of 0.47. The stock has a fifty day moving average of $734.15 and a 200-day moving average of $767.20. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business earned $3.92 EPS. The business's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LLY. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Leerink Partners reissued a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. JPMorgan Chase & Co. reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a report on Tuesday, September 16th. Finally, HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and upped their price objective for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.